moricizine (ethmozine) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Moricizine is an antiarrhythmic agent previously marketed as Ethmozine. It was used for prophylaxis and treatment of serious and life-threatening ventricular arrhythmias. In 2007 it was withdrawn and discontinued for commercial reasons. Moricizine can be administered intravenously but was more commonly provided as an oral formulation.   NCATS

Chemistry

  • SMILES: CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2
  • InChIKey: FUBVWMNBEHXPSU-UHFFFAOYSA-N
  • Mol. Mass: 427.53
  • ALogP: 4.11
  • ChEMBL Molecules:
    moricizine  
    moricizine hydrochloride  
More Chemistry

Pharmacology

Alternative names

[10-(3-morpholin-4-yl-propionyl)-10h-phenothiazin-2-yl]-carbamic acid ethyl ester | en-313 | ethmozin | ethmozine | ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate | ethyl 10-(beta-n-morpholinylpropionyl)phenothiazine-2-carbamate | etmozin | moracizin | moracizina | moracizine | moracizine hydrochloride | moracizinum | moricizine | moricizine hcl | moricizine hydrochloride

Organizations (16)

Research & Development (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Arrhythmias, Cardiac (approved 1990)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Arrhythmias, Cardiac (Phase 3)

Atrial Fibrillation (Phase 3)

Cardiovascular Diseases (Phase 3)

Coronary Disease (Phase 3)

Death, Sudden, Cardiac (Phase 3)

Heart Arrest (Phase 3)

Heart Diseases (Phase 3)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial Organizations: 15

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue